Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1Dermatologic 1

Conditions

Urogenital Neoplasms 1Neoplasm Metastasis 1Melanoma 1Liver Neoplasms 1Gastrointestinal Neoplasms 1Colonic Neoplasms 1

Interventions

pembrolizumab 5padeliporfin 5Nivolumab 5fludarabine 4aldesleukin 4Ipilimumab 4Cyclophosphamide 4atezolizumab 3Specimen Handling 3Paclitaxel 3Magnetic Resonance Spectroscopy 3Gemcitabine 3Carboplatin 3vedolizumab 2olaparib 2niraparib 2motexafin gadolinium 2cabozantinib 2anlotinib 2abiraterone 2Therapeutics 2Sunitinib 2Standard of Care 2Riluzole 2Radiation Dose Hypofractionation 2Prednisone 2Pluvicto 2Mitomycin 2LDP-02 2Infliximab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Urogenital Neoplasms × National Cancer Institute (U.S.) × Clear all
NCT03480152 2020-06-02

Messenger RNA (mRNA)-Based, Personalized Cancer Vaccine Against Neoantigens Expressed by the Autologous Cancer

National Institutes of Health Clinical Center (CC)

Phase 1/2 Terminated
5 enrolled 11 charts
DermatologicGastrointestinal

Colonic Neoplasms, Gastrointestinal Neoplasms, Liver Neoplasms, Melanoma, Neoplasm Metastasis, Urogenital Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡